Ixekizumab对中重度银屑病患者面部银屑病及健康相关生活质量的影响:两项III期试验12周结果
本研究合并分析两项III期随机双盲安慰剂对照活性药对照试验,纳入中重度银屑病患者,评估面部银屑病与健康相关生活质量的关系及Ixekizumab的疗效。结果显示面部银屑病对生活质量负面影响更大,Ixekizumab治疗后面部清除率显著高于依那西普和安慰剂,且面部清除与生活质量改善及PASI75/90达标正相关。
要点
- 面部银屑病对患者健康相关生活质量有显著负面影响。
- Ixekizumab治疗12周面部清除率显著优于依那西普和安慰剂。
- 面部清除与PASI75/90达标及生活质量改善独立相关。
核心结论
- 面部银屑病对健康相关生活质量的负面影响大于无面部银屑病。
- 面部银屑病清除与健康相关生活质量改善相关。
- Ixekizumab治疗患者面部快速清除显著多于依那西普和安慰剂,并带来更好临床结局。
研究设计与样本
- 两项III期多中心、随机、双盲、安慰剂对照、活性药对照试验的合并分析。
- 合并数据库纳入1133例有面部银屑病患者和1437例无面部银屑病患者。
- 患者接受安慰剂、依那西普50 mg每周两次或Ixekizumab(初始160 mg后80 mg每4周或每2周)治疗至12周。
主要发现
- Ixekizumab治疗后面部银屑病清除的患者第12周DLQI 0.1应答改善优于仍有面部银屑病者(P < 0.01)。
- 第12周,与仍有面部银屑病相比,面部清除在Ixekizumab每2周组中独立关联银屑病皮肤外观困扰评分显著改善(P < 0.01)。
- 第12周,Ixekizumab治疗患者中面部清除和整体PASI改善显著多于依那西普和安慰剂。
- 第12周,Ixekizumab或依那西普治疗患者面部银屑病清除与PASI75和PASI90达标正相关。
关键数值与推荐
- 面部银屑病在银屑病患者中报告率为17-68%。
- 依那西普剂量为50 mg每周两次。
- Ixekizumab剂量为初始160 mg后80 mg每4周或每2周。
临床怎么用
- 评估中重度银屑病患者时应关注面部受累及其对生活质量的影响。
- Ixekizumab可用于促进面部银屑病清除并改善相关生活质量。
- 面部清除与PASI75/90达标相关,可作为治疗目标参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Facial psoriasis was reported in 17-68% of patients with psoriasis and shown to have a negative impact on patients' personal and health-related quality of life (HRQoL). OBJECTIVES: To explore the association of facial psoriasis with patients' HRQoL and to assess the relationship between ixekizumab (IXE) and improvement in facial psoriasis and changes in HRQoL. METHODS: This work reports the combined results of two phase III multicentre, randomized, double-blind, placebo-controlled, active-comparator trials in patients with moderate-to-severe psoriasis. Patients received placebo, etanercept (ETN; 50 mg twice weekly) or IXE [80 mg every 4 weeks (Q4W) or every 2 weeks (Q2W)] for up to 12 weeks following an initial 160-mg dose. HRQoL parameters were analysed based on facial psoriasis status at baseline using analysis of covariance models. Improvement was assessed as percentage of patients with no facial psoriasis. RESULTS: The combined database included 1133 patients with facial psoriasis and 1437 without. Patients treated with IXE whose facial psoriasis cleared had improved Dermatology Life Quality Index 0.1 responses (P < 0.01) compared with patients with facial psoriasis at Week 12. At Week 12, clearance of facial psoriasis compared with the presence of facial psoriasis was independently associated with significantly better improvement in Psoriasis Skin Appearance Bothersomeness scores in the IXE Q2W treatment group (P < 0.01). At Week 12, facial clearance and overall Psoriasis Area Severity Index (PASI) improvement were observed in significant numbers of patients treated with IXE compared with ETN and placebo. Facial psoriasis clearance at Week 12 in patients treated with IXE or ETN was positively associated with PASI75 and PASI90 achievement. CONCLUSION: Facial psoriasis had a larger negative impact on HRQoL than no facial psoriasis. Facial psoriasis clearance was associated with improved HRQoL. Significantly more IXE-treated patients had rapid facial clearance vs. ETN and PBO, which led to better clinical outcomes.
引用
- Paul C, Guenther L, Torii H, et al. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. J Eur Acad Dermatol Venereol. 2017. PMID: 28881462. doi:10.1111/jdv.14581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。